💊 Goldline Pharmaceutical IPO Subscription Day 1 Report — 12 May 2026
The Goldline Pharmaceutical IPO opened for subscription today on 12 May 2026 on the BSE SME platform. The Nagpur-based pharma marketing company is raising ₹11.61 crore via a fresh issue at a price band of ₹41–₹43 per share. Issue closes on 14 May 2026, with listing expected on 19 May 2026.
📊 Day 1 Subscription Status — Category Wise
• Overall Subscription: Day 1 figures for Goldline Pharmaceutical IPO subscription status are at an early stage. Bidding has just begun and numbers will build up through the day.
• Retail (RII) Category: Retail bids for Goldline Pharmaceutical IPO are being recorded. Since the issue is currently undersubscribed, allotment chances are higher for early applicants.
• NII / HNI Category: Initial NII participation is being recorded. HNIs typically ramp up bids on Day 2 and Day 3 in BSE SME IPOs of this size.
• QIB Category: No significant QIB activity expected on Day 1 for Goldline Pharmaceutical IPO. Institutional interest will reflect more clearly by Day 3.
• IPOCloud Day 1 Assessment: Day 1 data is still early for Goldline Pharmaceutical IPO. Investors should track live subscription numbers on IPOCloud and revisit before Day 3 close on 14 May 2026.
📈 Goldline Pharmaceutical IPO GMP Today — 12 May 2026
The Goldline Pharmaceutical IPO GMP today stands at ₹8, suggesting an expected listing price of around ₹51 — approximately 18.6% above the upper price band of ₹43. Grey market interest is steady ahead of the 19 May 2026 listing on BSE SME.
Track live Goldline Pharmaceutical IPO GMP updates on IPOCloud for day-wise premium movement.
🏭 Company Overview — Goldline Pharmaceutical Ltd
Goldline Pharmaceutical Limited was founded on 28 February 2005 by Mr. Amol Laxmikant Mujumdar and is based in Nagpur, Maharashtra. The company markets pharmaceutical products under its proprietary "Goldline" brand across five segments — Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness — covering specialties including cardiology, diabetology, pediatrics, neurology, oncology wellness, and general medicine.
The company follows an entirely asset-light model — outsourcing all manufacturing to 15 third-party contract manufacturers while focusing on branding, marketing, and distribution. It has a portfolio of nearly 146 products distributed primarily across Maharashtra and Madhya Pradesh through 7–8 major distributors.
📋 IPO Key Details
• Exchange: BSE SME
• Issue Size: ₹11.61 Crore (Fresh Issue Only, No OFS)
• Price Band: ₹41 – ₹43 per share
• Lot Size: 3,000 shares | Min. Investment: ₹2,58,000 (2 lots)
• Open Date: 12 May 2026 | Close Date: 14 May 2026
• Allotment Date: 15 May 2026
• Listing Date: 19 May 2026
• Registrar: Bigshare Services Pvt. Ltd.
• Lead Manager: Cumulative Capital Pvt. Ltd.
💰 Financials — FY25 Performance
• Revenue from Operations: ₹28.06 Crore (FY25) vs ₹23.57 Crore (FY24) — ~19% growth
• Profit After Tax (PAT): ₹2.83 Crore (FY25) vs ₹1.81 Crore (FY24)
• Revenue CAGR FY23–FY25: ~19–20%
• P/E Ratio: 10.48x at upper band (fairly priced vs industry avg of 18.26x)
• ROE FY25: 27.34% (improved from 4.41% in FY23)
• IPO Proceeds Use: ₹8.90 Crore towards repayment of existing borrowings
✅ Should You Apply?
The Goldline Pharmaceutical IPO presents a niche pharma marketing play with consistent revenue and PAT growth, strong ROE improvement, and attractive valuations at 10.48x P/E vs an industry average of 18.26x. Key risks include geographic concentration (Maharashtra + MP = 76% revenue), heavy dependence on third-party manufacturers, and promoter-group related-party revenue of 22%. GMP of ₹8 indicates ~18.6% potential listing gain. Selective investors with moderate risk appetite may consider applying. Track live subscription status on IPOCloud before applying on Day 2 or Day 3.
Disclaimer: This is not investment advice. Please read the RHP carefully and consult your financial advisor before investing. Grey market premium (GMP) is unofficial and unregulated.